Triethylamine → (s)-2-[4-(2,3-Dichloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-n-[1-(2-hydroxy-2-methyl-propyl)-1h-pyrazol-3-yl]-3-(tetrahydro-pyran-2-yl)-propionamide

HRID 19034

反応式

HRID 19034 の反応式
Cl.[NH2:2][C@@H:3]([CH2:17][CH:18]1[CH2:23][CH2:22][CH2:21][CH2:20][O:19]1)[C:4]([NH:6][C:7]1[CH:11]=[CH:10][N:9]([CH2:12][C:13]([OH:16])([CH3:15])[CH3:14])[N:8]=1)=[O:5].C(N(CC)CC)C.Cl.OC(C)(C)CN1C=CC(NC(=O)[C@@H](N2[CH2:51][C:50]([O:52][C:53]3[CH:58]=[CH:57][CH:56]=[C:55]([Cl:59])[C:54]=3[Cl:60])=[CH:49][C:48]2=[O:61])CC(C)C)=N1>CO>[Cl:60][C:54]1[C:55]([Cl:59])=[CH:56][CH:57]=[CH:58][C:53]=1[O:52][C:50]1[CH2:51][N:2]([C@@H:3]([CH2:17][CH:18]2[CH2:23][CH2:22][CH2:21][CH2:20][O:19]2)[C:4]([NH:6][C:7]2[CH:11]=[CH:10][N:9]([CH2:12][C:13]([OH:16])([CH3:14])[CH3:15])[N:8]=2)=[O:5])[C:48](=[O:61])[CH:49]=1

参加物

5

反応物 3

HCID 8471TriethylamineHCID 66899077(S)-2-[4-(2,3-dichloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-amide hydrochlorideHCID 67504601(S)-2-amino-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-3-(tetrahydropyran-2-yl)-propionamide hydrochloride

生成物 1

HCID 57920027(s)-2-[4-(2,3-Dichloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-n-[1-(2-hydroxy-2-methyl-propyl)-1h-pyrazol-3-yl]-3-(tetrahydro-pyran-2-yl)-propionamide収率 3.7%

試薬・触媒・溶媒 1

HCID 887Methanol溶媒

実験手順

(S)-2-amino-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-3-(tetrahydropyran-2-yl)-propionamide hydrochloride (118 mg, 0.30 mmol) was dissolved in methanol (2 mL) and triethylamine (0.2 mL) was added. The mixture was evaporated to dryness. The residue was dissolved in acetonitrile (5 mL). To this solution was added (E)-4-bromo-3-(2,3-dichloro-phenoxy)-but-2-enoic acid ethyl ester (prepared as in Example 77, 109 mg, 0.30 mmol). The mixture was refluxed for 40 h. The mixture was evaporated and the residue was treated with ethyl acetate and water. The layers were separated and the organic layer was dried over sodium sulfate and concentrated to give a crude product (180 mg). One part of the crude product (30 mg) was purified through reverse phase preparative HPLC (acetonitrile in water, 25% to 100% linear gradient) to afford (S)-2-[4-(2,3-dichloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-3-(tetrahydro-pyran-2-yl)-propionamide as a white powder (6 mg): LR-ES-MS m/z calculated for C25H30Cl2N4O5 [M]+ 536, observed [M+H]+ 537; 1H-NMR (CDCl3) δ ppm 1.16 (s, 6H), 1.25-1.73 (m, 5H), 1.73-2.00 (m, 2H), 2.17-2.34 (m, 1H), 3.29-3.49 (m, 2H), 3.88-4.06 (m, 3H), 4.24 (d, J=17.8 Hz, 1H), 4.42 (d, J=17.8 Hz, 1H), 4.89 (s, 1H), 5.02-5.16 (m, 1H), 6.70 (br s, 1H), 7.14-7.23 (m, 1H), 7.28-7.37 (m, 3H), 7.42 (d, J=8.2 Hz, 1H), 8.76 (br s, 1H).

後処理

  1. customThe mixture was evaporated to dryness
  2. dissolutionThe residue was dissolved in acetonitrile (5 mL)
  3. temperatureThe mixture was refluxed for 40 h
  4. customThe mixture was evaporated
  5. additionthe residue was treated with ethyl acetate and water
  6. customThe layers were separated
  7. dry with materialthe organic layer was dried over sodium sulfate
  8. concentrationconcentrated
  9. customto give a crude product (180 mg)
  10. customOne part of the crude product (30 mg) was purified through reverse phase preparative HPLC (acetonitrile in water, 25% to 100% linear gradient)

出典と根拠

ORDレコード
ord-bfbb81b677a2437da9cee6c0e70db2a5
出典データセット
uspto-grants-2010_06
特許番号
US07741327B2

関連ノート

読み込み中…